ArticleScientific reports2026
In-silico screening of marine fungal metabolites identifies potential FtsZ inhibitors against MDR-tuberculosis through docking and molecular dynamics analysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pharmacophore-based virtual screening, molecular docking, MD simulation, MM-GBSA energy calculation and DFT analysis for theRSC advances · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) remains a major global health challenge, intensified by the rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis. The bacterial cell division protein FtsZ, a key GDPase required for cytokinesis, represents a promising target for novel anti-TB therapeutics. This study aimed to identify potential FtsZ inhibitors among marine fungal metabolites using molecular docking, molecular dynamics (MD) simulations, and MM/GBSA analyses. Docking was performed with AutoDock Vina v1.2.0, followed by 200 ns MD simulations using Desmond to evaluate complex stability. Among 100 screened metabolites, Xanalteric acid II showed the strongest binding affinity (- 10.9 kcal/mol), interacting with Arg140 and Thr130 within the active site, outperforming the co-crystallized ligand (- 9.1 kcal/mol) and moxifloxacin (- 7.7 kcal/mol). The FtsZ-Xanalteric acid II complex exhibited stable RMSD and compact radius of gyration throughout the simulation. MM/GBSA analysis revealed a strong binding free energy (ΔG_bind = - 74.77 ± 4.95 kcal/mol), dominated by van der Waals and lipophilic interactions. PCA, FEL, and DCCM analyses confirmed the structural rigidity and energetic stability of the complex. These findings highlight Xanalteric acid II as a promising marine-derived inhibitor of FtsZ and support the potential of marine metabolites in developing next-generation anti-TB agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.